• SEC Filings

Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Regulation FD Disclosure
Item 7.01

Regulation FD Disclosure.

On December 3, 2018, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing updated data from its ongoing Phase 2 clinical trial of KD025, its selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), in patients with previously treated chronic graft-versus-host disease (cGVHD). The data were presented on Monday, December 3, 2018 in an oral presentation at the 60th American Society of Hematology (“ASH”) Annual Meeting in San Diego, CA.

The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. A copy of the presentation will be available on the Investors section of the Company’s website at www.kadmon.com beginning December 3, 2018, and will remain available in accordance with the Company’s policies.

The information in this Item 7.01, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or into any filing or other document to the Exchange Act, except as otherwise expressly stated in any such filing.

(d) Exhibits

Kadmon Holdings, Inc. Exhibit
EX-99.1 2 kdmn-20181203xex99_1.htm EX-99.1 991 Press Release cGVHD Data ASH 2018 Exhibit 99.1   Kadmon Announces Updated Findings from Ongoing Phase 2 Clinical Trial of KD025 in cGVHD at ASH Annual Meeting NEW YORK,…
To view the full exhibit click here

About Kadmon Holdings, Inc. (NYSE:KDMN)

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.